NV-DENODO
8.4.2024 13:01:48 CEST | Business Wire | Press release
GOOGLE CLOUD NEXT, Booth 1362 - Denodo, a leader in data management, announced a new integration of the Denodo Platform with Google Cloud’s Vertex AI as part of its partnership. Powered by data virtualization, the Denodo Platform will work with Google Cloud to empower joint customers to drive innovative solutions by combining advanced logical data management capabilities with cutting-edge generative AI services while providing access to state-of-the-art large language models (LLM). To learn more see the demo or meet Denodo at the event in booth number 1362.
“Google Cloud and Denodo’s innovative technologies enable us to provide better and faster insights while freeing up valuable time and resources for our team,” said Dan Young, chief data architect at Indiana University. “We recognized early on the transformative potential that can be realized by combining Denodo’s data management platform with Google Cloud’s generative AI solutions and, in particular, their large language model capabilities which empower our academic community by accelerating cutting-edge research and advancing the success of our students.”
Enterprises across industries, including financial services, healthcare, manufacturing, retail, telecommunications, and higher education, are actively seeking to transform their businesses by leveraging the power of generative AI. This integration provides an opportunity for organizations to drive real transformation by enabling access to Gemini models and the ability to develop exciting new services and applications.
“Generative AI can significantly improve how businesses operate and benefit virtually every industry,” said Ritika Suri, Technology Partnerships director, at Google Cloud. “By utilizing Google Cloud’s leading gen AI capabilities, Denodo can help customers unlock new insights that help them improve operations and be more productive.”
Google Cloud accelerates an organizations' ability to digitally transform their business by combining its strong infrastructure platform, industry solutions, and expertise. Coupled with the power of Google Cloud’s generative AI and LLMs, organizations leverage the Denodo Platform to responsibly ensure ethical considerations like bias mitigation, privacy protection, and human oversight by safely and efficiently feeding data to Vertex AI applications.
“Using Denodo’s logical/semantic-model approach, enterprises across industries can integrate and manage data and apply Retrieval Augmented Generation (RAG) techniques that combine the capabilities of a pre-trained large language model with external data sources,” said Narayan Sundar, senior director, Strategic Alliances, Denodo. “This latest integration further sets the stage for enterprises to redefine the boundaries of innovation by unlocking new levels of business value through the power of data and generative AI. As a longtime partner of Google Cloud, we enhance the capabilities of large language models by enabling them to query authoritative and relevant data and offer nuanced responses that deliver unprecedented business insights.”
Additional Information:
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408505083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom